Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

xencor inc - XNCR

XNCR

Close Chg Chg %
13.96 -1.42 -10.17%

Open Market

12.54

-1.42 (10.17%)

Volume: 2.41M

Last Updated:

Oct 14, 2025, 3:43 PM EDT

Trade Now

Company Overview: xencor inc - XNCR

XNCR Key Data

Open

$13.95

 Day Range

11.17 - 13.98

52 Week Range

6.92 - 27.24

 Market Cap

$995.67M

Shares Outstanding

71.32M

 Public Float

66.91M

Beta

0.96

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.42

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.25M

  

XNCR Performance

1 Week
 
 7.14%
 
1 Month
 
 62.33%
 
3 Months
 
 55.63%
 
1 Year
 
 -35.90%
 
5 Years
 
 -65.87%
 

XNCR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13
Full Ratings ➔

About xencor inc - XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

XNCR At a Glance

Xencor, Inc.
465 North Halstead Street
Pasadena, California 91016
Phone 1-626-305-5900 Revenue 110.49M
Industry Biotechnology Net Income -232,618,000.00
Sector Health Technology Employees 250
Fiscal Year-end 12 / 2025
View SEC Filings

XNCR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 13.527
Price to Book Ratio 2.383
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.368
Enterprise Value to Sales 11.089
Total Debt to Enterprise Value 0.189

XNCR Efficiency

Revenue/Employee 441,972.00
Income Per Employee -930,472.00
Receivables Turnover 1.816
Total Asset Turnover 0.115

XNCR Liquidity

Current Ratio 6.606
Quick Ratio 6.606
Cash Ratio 5.693

XNCR Profitability

Gross Margin 89.043
Operating Margin -161.465
Pretax Margin -212.613
Net Margin -210.527
Return on Assets -24.268
Return on Equity -34.736
Return on Total Capital -25.575
Return on Invested Capital -26.728

XNCR Capital Structure

Total Debt to Total Equity 34.231
Total Debt to Total Capital 25.502
Total Debt to Total Assets 24.366
Long-Term Debt to Equity 26.637
Long-Term Debt to Total Capital 19.844
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xencor Inc - XNCR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
275.11M 164.58M 174.62M 110.49M
Sales Growth
+124.23% -40.18% +6.10% -36.72%
Cost of Goods Sold (COGS) incl D&A
7.49M 8.80M 11.50M 12.11M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.49M 8.80M 11.50M 12.11M
Depreciation
6.29M 7.40M 10.20M 10.81M
Amortization of Intangibles
1.20M 1.40M 1.30M 1.30M
COGS Growth
- +17.46% +30.67% +5.30%
Gross Income
267.62M 155.78M 163.12M 98.39M
Gross Income Growth
- -41.79% +4.71% -39.68%
Gross Profit Margin
+97.28% +94.65% +93.42% +89.04%
2021 2022 2023 2024 5-year trend
SG&A Expense
222.95M 236.75M 295.48M 276.79M
Research & Development
192.51M 199.56M 253.60M 227.69M
Other SG&A
30.45M 37.19M 41.88M 49.11M
SGA Growth
+15.40% +6.19% +24.80% -6.32%
Other Operating Expense
- - - -
-
Unusual Expense
- (20.09M) (21.93M) 19.15M
EBIT after Unusual Expense
64.75M (59.04M) (132.36M) (197.56M)
Non Operating Income/Expense
17.88M 4.53M 18.91M (722.00K)
Non-Operating Interest Income
849.00K 4.82M 19.33M 31.93M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 6.18M 36.64M
-
Interest Expense Growth
- - - +493.22%
-
Gross Interest Expense
- - 6.18M 36.64M
-
Interest Capitalized
- - - -
-
Pretax Income
82.63M (54.51M) (119.63M) (234.92M)
Pretax Income Growth
+219.18% -165.97% -119.48% -96.37%
Pretax Margin
+30.04% -33.12% -68.51% -212.61%
Income Tax
- 673.00K 13.66M 1.62M
Income Tax - Current - Domestic
- - 13.66M 1.62M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
82.63M (55.18M) (133.30M) (236.54M)
Minority Interest Expense
- - (163.00K) (3.92M)
-
Net Income
82.63M (55.18M) (133.13M) (232.62M)
Net Income Growth
+219.18% -166.78% -141.27% -74.73%
Net Margin Growth
+30.04% -33.53% -76.24% -210.53%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
82.63M (55.18M) (133.13M) (232.62M)
Preferred Dividends
- - - -
-
Net Income Available to Common
82.63M (55.18M) (133.13M) (232.62M)
EPS (Basic)
1.4154 -0.925 -2.2004 -3.5765
EPS (Basic) Growth
+216.79% -165.35% -137.88% -62.54%
Basic Shares Outstanding
58.38M 59.65M 60.50M 65.04M
EPS (Diluted)
1.3659 -0.925 -2.2004 -3.5765
EPS (Diluted) Growth
+212.71% -167.72% -137.88% -62.54%
Diluted Shares Outstanding
60.50M 59.65M 60.50M 65.04M
EBITDA
52.16M (72.17M) (120.86M) (166.30M)
EBITDA Growth
+173.98% -238.38% -67.46% -37.59%
EBITDA Margin
+18.96% -43.85% -69.22% -150.51%

Snapshot

Average Recommendation BUY Average Target Price 25.545
Number of Ratings 13 Current Quarters Estimate -0.757
FY Report Date 12 / 2025 Current Year's Estimate -2.559
Last Quarter’s Earnings -0.775 Median PE on CY Estimate N/A
Year Ago Earnings -3.58 Next Fiscal Year Estimate -2.933
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 7 13 13
Mean Estimate -0.76 -0.73 -2.56 -2.93
High Estimates -0.17 -0.45 -1.95 -1.38
Low Estimate -1.00 -0.90 -3.04 -3.58
Coefficient of Variance -30.12 -25.09 -12.93 -24.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 10 11
OVERWEIGHT 0 0 0
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Buy Overweight Buy

Insider Actions for Xencor Inc - XNCR

Date Name Shares Transaction Value
Apr 15, 2025 Bart Cornelissen SR. VICE PRESIDENT & CFO 61,348 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.06 per share 494,464.88
Mar 14, 2025 Todd E. Simpson Director 43,337 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Bassil I. Dahiyat PRESIDENT & CEO; Director 465,419 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.6 per share 6,329,698.40
Mar 12, 2025 John R. Desjarlais SR. VICE PRESIDENT & CSO 236,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.6 per share 3,217,406.40
Mar 12, 2025 Nancy Valente EVP, Chief Development Officer 53,785 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.6 per share 731,476.00
Mar 12, 2025 Celia E. Eckert SVP, GENERAL COUNSEL 63,507 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.6 per share 863,695.20
Mar 6, 2025 Bassil I. Dahiyat PRESIDENT & CEO; Director 329,236 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 John R. Desjarlais SR. VICE PRESIDENT & CSO 89,552 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Celia E. Eckert SVP, GENERAL COUNSEL 65,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Bart Cornelissen SR. VICE PRESIDENT & CFO 65,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2024 Bassil I. Dahiyat PRESIDENT & CEO; Director 366,163 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.69 per share 5,745,097.47
Nov 26, 2024 Bassil I. Dahiyat PRESIDENT & CEO; Director 22,356 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Bassil I. Dahiyat PRESIDENT & CEO; Director 8,808 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Xencor Inc in the News